These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9069553)

  • 41. [The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia].
    D'iakov SI; Bubnov VP; Lebedeva IK; Sidorenko SV; Moskalenko VI
    Antibiot Khimioter; 2000; 45(6):17-20. PubMed ID: 10904804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of parenteral administration of three antimicrobial agents in treatment of clinical mastitis in lactating cows: 487 cases (1989-1995).
    Pyörälä SH; Pyörälä EO
    J Am Vet Med Assoc; 1998 Feb; 212(3):407-12. PubMed ID: 9470054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
    Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
    Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
    Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparative evaluation of the effectiveness of fluoroquinolones in experimental anthrax infection].
    D'iakov SI; Katsalukha VV; Lebedeva IK; Lukashina AV; Raĭskaia VA
    Antibiot Khimioter; 1994 Jun; 39(6):15-9. PubMed ID: 7848000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Resistance and new antibiotic strategies. New antistaphylococcal antibiotics].
    Bergogne-Bérézin E
    Presse Med; 2000 Dec; 29(37):2023-7. PubMed ID: 11155724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
    Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
    J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.
    Blumberg HM; Rimland D; Carroll DJ; Terry P; Wachsmuth IK
    J Infect Dis; 1991 Jun; 163(6):1279-85. PubMed ID: 2037793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
    Chandrasekar PH; Levine DP; Price S; Rybak MJ
    J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.
    Nord CE
    Infection; 1999; 27(3):166-72. PubMed ID: 10378126
    [No Abstract]   [Full Text] [Related]  

  • 55. Bacterial resistance to fluoroquinolones: mechanisms and patterns.
    Hooper DC
    Adv Exp Med Biol; 1995; 390():49-57. PubMed ID: 8718601
    [No Abstract]   [Full Text] [Related]  

  • 56. Fluoroquinolones.
    Levine AM; DiBona JR
    J Am Acad Orthop Surg; 2002; 10(1):1-4. PubMed ID: 11809044
    [No Abstract]   [Full Text] [Related]  

  • 57. Fluoroquinolones and leukopenia: the mechanism.
    Ahmad S
    South Med J; 1990 Nov; 83(11):1366-7. PubMed ID: 2173151
    [No Abstract]   [Full Text] [Related]  

  • 58. Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.
    Goulenok T; Fantin B
    Clin Pharmacokinet; 2013 Oct; 52(10):869-83. PubMed ID: 23807657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.
    Shapiro MA; Dever JA; Sesnie JC; VanderRoest SR
    J Antimicrob Chemother; 1997 Feb; 39(2):273-6. PubMed ID: 9069553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.